BeStock  

United Therapeutics UTHR

US equityMarket cap rank #819Drug Manufacturers - Specialty & Generic
$554.73 −$4.37 (-0.78%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $550.23 -0.81%
Open$561.20
Prev close$559.10
Day range$551.77 – $563.12
Volume531.8K
Market cap$23.63B
P/E (TTM)20.9
Dividend yield–

Earnings

Average move on report day±4.7%last 16 reports
Closed higher11 of 1669% of the time
Best reaction+13.0%
Worst reaction-10.8%

Stock move on the day after each report

+2.3%2023/Q4+8.9%2024/Q1-7.2%2024/Q2+2.4%2024/Q3-10.8%2024/Q4+0.8%2025/Q1-5.2%2025/Q2+9.6%2025/Q3+13.0%2025/Q4+4.3%2026/Q1+0.1%2026/Q2+1.2%2026/Q3
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q34 Nov 2026Pre Market±6.6%+1.19%Within range
2026/Q25 Aug 2026Pre Market±6.4%+0.06%Within range
2026/Q16 May 2026Pre Market±7.6%+4.29%Within range
2025/Q425 Feb 2026Pre Market±9.1%+13.03%Bigger than priced
2025/Q329 Oct 2025Pre Market±9.9%+9.63%Within range
2025/Q230 Jul 2025Pre Market±9.5%-5.25%Within range
2025/Q130 Apr 2025Pre Market±7.4%+0.77%Within range
2024/Q426 Feb 2025Pre Market±9.1%-10.80%Bigger than priced
2024/Q330 Oct 2024Pre Market±7.4%+2.44%Within range
2024/Q231 Jul 2024Pre Market±8.0%-7.18%Within range
2024/Q11 May 2024Pre Market±8.2%+8.88%Bigger than priced
2023/Q421 Feb 2024Pre Market±8.8%+2.34%Within range
2023/Q31 Nov 2023Pre Market±7.2%+0.55%Within range
2023/Q22 Aug 2023Pre Market±5.8%+0.30%Within range
2023/Q13 May 2023Pre Market±8.5%-4.54%Within range
2022/Q422 Feb 2023Pre Market±8.9%-4.51%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2026/Q3

By business line

  • Tyvaso DPI$378.50M 45.5%
  • Orenitram$145.00M 17.4%
  • Nebulized Tyvaso$125.30M 15.1%
  • Remodulin$122.00M 14.7%
  • Unituxin$52.30M 6.3%
  • Other$4.90M 0.6%
  • Adcirca$4.50M 0.5%

Latest reported quarter: Q3, ended Sep 2026

Revenue$832.50M+4.1% YoY
Operating profit$241.30M-38.0% YoY
Net profit$258.60M-23.6% YoY
Diluted EPS$5.71-20.3% YoY
Free cash flow$125.80M-64.2% YoY
Operating cash flow$306.50M

Revenue, last 8 quarters

$735.9MDec '24$794.4MMar '25$798.6MJun '25$799.5MSep '25$790.2MDec '25$781.5MMar '26$783.3MJun '26$832.5MSep '26

Net profit, last 8 quarters

$301.3MDec '24$322.2MMar '25$309.5MJun '25$338.7MSep '25$364.3MDec '25$274.9MMar '26$333.0MJun '26$258.6MSep '26

Profitability & balance sheet

Gross margin86.3%
Operating margin39.4%
Net margin38.6%
Return on equity19.1%
Return on assets17.1%
Return on invested capital17.4%
Current ratio4.61
Liabilities / assets10.8%
Cash & investments$2.07B
Net cash (debt)$2.07B
Free cash flow / sales27.0%

Discussion

No comments yet — be the first to weigh in on UTHR.

Sign in to join the discussion.

Scroll to Top